Skip to content
value.today
BioNanomatrix Inc logo

BioNanomatrix Inc

Formerly BioNanomatrix LLC

Total raised
$118 M
5 rounds on record
Latest round
$68 M
Sep 2014
First round on record
Mar 2011
Today
Went public
See the company page

BioNanomatrix Inc is listed today as Bionano Genomics, Inc.: market value, financials and filings are on its company page.

Funding rounds

5 counted as startup funding, 5 other private sales on record. Open the number of investors for the round's details.

Funding rounds of BioNanomatrix Inc
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2024$20 MPrivate placement after listing$10 to $50 million

BioNanomatrix Inc: Private sale, Jul 2024

Investors in this round

2 investors had bought by the notice of Jul 10, 2024: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for BioNanomatrix Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$20 M of $20 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$400,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alka A. Chaubey · Executive Officer
  • Gulsen Erik Kama · Executive Officer
  • Jonathan A. Dixon · Executive Officer
  • Mark A. Oldakowski · Executive Officer
  • R. Erik Holmlin · Executive Officer, Director
  • Albert A. Luderer · Director
  • Aleksandar A. Rajkovic · Director
  • Christopher A. Twomey · Director
  • David L. Barker · Director
  • Hannah A. Mamuszka · Director
  • Kristiina A. Vuori · Director
  • Vincent A. Wong · Director
  • Yvonne L. Linney · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co., LLC (CRD 375) · New York, New YorkSold in all US states

Signed by R. Erik Holmlin, President and CEO. Source: SEC Form D, newest notice filed Jul 10, 2024. Read the notice at the SEC.

optionsSEC
May 2024$20 MPrivate placement after listing$10 to $50 million

BioNanomatrix Inc: Private sale, May 2024

Investors in this round

4 investors had bought by the notice of Jun 5, 2024: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for BioNanomatrix Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$20 M of $20 M offered
Smallest investment taken
$100,000
What was sold
equity, debt
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,275,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • R. Erik Holmlin · Executive Officer

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Canaccord Genuity LLC (CRD 1020) · New York, New YorkSold in CT, NY

Signed by R. Erik Holmlin, President and CEO. Source: SEC Form D, newest notice filed Jun 5, 2024. Read the notice at the SEC.

equity, debtSEC
Oct 2023$35 MPrivate placement after listing$10 to $50 million

BioNanomatrix Inc: Private sale, Oct 2023

Investors in this round

1 investor had bought by the notice of Oct 27, 2023: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for BioNanomatrix Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$35 M of $35 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alka Chaubey, Ph.D., FACMG · Executive Officer
  • Gulsen Kama · Executive Officer
  • Mark Oldakowski · Executive Officer
  • R. Erik Holmlin, Ph.D. · Executive Officer, Director
  • Albert A. Luderer, Ph.D. · Director
  • Aleksandar A. Rajkovic, M.D., Ph.D. · Director
  • Christopher A. Twomey · Director
  • David L. Barker, Ph.D. · Director
  • Hannah A. Mamuszka · Director
  • Kristiina A. Vuori, M.D., Ph.D. · Director
  • Vincent A. Wong, J.D., M.B.A. · Director
  • Yvonne A. Linney, Ph.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by R. Erik Holmlin, Ph.D., President and Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 27, 2023. Read the notice at the SEC.

debt, optionsSEC
Oct 2021$42 MPrivate placement after listing$10 to $50 million

BioNanomatrix Inc: Private sale, Oct 2021

Investors in this round

27 investors had bought by the notice of Oct 25, 2021: 8 accredited, 19 not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for BioNanomatrix Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$42 M of $42 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alka Chaubey, Ph.D., FACMG · Executive Officer
  • Christopher Stewart · Executive Officer
  • Jason A. Priar · Executive Officer
  • Mark Oldakowski · Executive Officer
  • R. Erik Holmlin, Ph.D. · Executive Officer, Director
  • Richard A. Shippy · Executive Officer
  • Soheil A. Shams · Executive Officer
  • Albert A. Luderer, Ph.D. · Director
  • Christopher A. Twomey · Director
  • David L. Barker, Ph.D. · Director
  • Hannah A. Mamuszka · Director
  • Kristiina A. Vuori, M.D., Ph.D. · Director
  • Yvonne A. Linney, Ph.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by R. Erik Holmlin, Ph.D., President and Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 25, 2021. Read the notice at the SEC.

equitySEC
Mar 2019$3 MPrivate placement after listing$2 to $10 million

BioNanomatrix Inc: Private sale, Mar 2019

Investors in this round

3 investors had bought by the notice of Mar 28, 2019: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for BioNanomatrix Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$3 M of $12 M offered; $9 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
not stated
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Mark Borodkin · Executive Officer
  • Mike Ward · Executive Officer
  • R. Erik Holmlin, Ph.D. · Executive Officer, Director
  • Warren Robinson · Executive Officer
  • Albert L. Luderer, Ph.D. · Director
  • Christopher L. Twomey · Director
  • Darren L. Cai, Ph.D. · Director
  • David L. Barker, Ph.D. · Director
  • Junfeng L. Wang · Director
  • Quan L. Zhou · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by /s/ R. Erik Holmlin, Ph.D., President and Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 28, 2019. Read the notice at the SEC.

equitySEC
Sep 2014$68 MNo. 5$50 to $250 million

BioNanomatrix Inc: Raise no. 5, Sep 2014

Investors in this round

17 investors had bought by the notice of Jan 27, 2015: 17 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for BioNanomatrix Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$68 M of $68 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, other: Securities offered consist of Warrants exercisable for shares of Series C Preferred Stock, the Series C Preferred Stock issuable upon exercise of the warrants and the common stock underlying the Serie
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Erik R. Holmlin · Executive Officer, Director
  • Han R. Cao · Executive Officer
  • Joel R. Jung · Executive Officer
  • Albert R. Luderer · Director
  • Brian R. Halak · Director
  • Campbell R. Murray · Director
  • Darren R. Cai · Director
  • David R. Barker · Director
  • Tracy R. Warren · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The amount listed above includes the amount receivable upon the exercise of warrants to purchase shares of Series C Preferred Stock. Such warrants have not yet been exercised.”

Signed by Joel Jung, Chief Financial Officer. Source: SEC Form D, newest notice filed Jan 27, 2015. Read the notice at the SEC.

equity, optionsSEC
Jun 2014$5 MNo. 4$2 to $10 million

BioNanomatrix Inc: Raise no. 4, Jun 2014

Investors in this round

5 investors had bought by the notice of Jun 27, 2014: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for BioNanomatrix Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$5 M of $6 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Han A. Cao · Executive Officer
  • Joel R. Jung · Executive Officer
  • R. Erik Holmlin · Executive Officer
  • Albert A. Luderer · Director
  • Brian L. Halak · Director
  • David L. Barker · Director
  • Tracy A. Warren · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Total offering amount listed above includes an aggregate of $1,039,997 receivable upon the exercise of warrants to purchase shares of the Company's Series B-1 Preferred Stock. Such warrants have not yet been exercised.”

Signed by Joel Jung, Chief Financial Officer. Source: SEC Form D, newest notice filed Jun 27, 2014. Read the notice at the SEC.

debt, optionsSEC
Sep 2013$10 MNo. 3$10 to $50 million

BioNanomatrix Inc: Raise no. 3, Sep 2013

Investors in this round

5 investors had bought by the notice of Oct 2, 2013: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for BioNanomatrix Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$10 M of $14 M offered; $4 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Han A. Cao · Executive Officer
  • R. Erik Holmlin · Executive Officer, Director
  • Albert A. Luderer · Director
  • Brian L. Halak · Director
  • David L. Barker · Director
  • Tracy A. Warren · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Total Offering Amount listed above includes an aggregate of $3,110,509 receivable upon the exercise of warrants to purchase shares of the Company's Series B-1 preferred stock. Such warrants have not yet been exercised.”

Signed by Erik Holmlin, Ph.D., President and CEO. Source: SEC Form D, newest notice filed Oct 2, 2013. Read the notice at the SEC.

debt, optionsSEC
Jun 2012$12 MNo. 2$10 to $50 million

BioNanomatrix Inc: Raise no. 2, Jun 2012

Investors in this round

6 investors had bought by the notice of Jul 5, 2012: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for BioNanomatrix Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$12 M of $14 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them, other: Securities offered consist of shares of convertible preferred stock, the convertible preferred stock issued upon exercise of the warrants and the common stock underlying the convertible preferred stoc
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Garth A. Monroe · Executive Officer
  • Han A. Cao · Executive Officer
  • R. Erik Holmlin · Executive Officer, Director
  • Albert A. Luderer · Director
  • Brian L. Halak · Director
  • David L. Barker · Director
  • Tracy A. Warren · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Amounts listed above include an aggregate of $2,787,501 receivable upon the exercise of warrants to purchase shares of convertible preferred stock. Such warrants have not yet been exercised.”

Signed by Garth Monroe, Cfo. Source: SEC Form D, newest notice filed Jul 5, 2012. Read the notice at the SEC.

equity, optionsSEC
Mar 2011$23 MNo. 1$10 to $50 million

BioNanomatrix Inc: Raise no. 1, Mar 2011

Investors in this round

9 investors had bought by the notice of Mar 24, 2011: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for BioNanomatrix Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$23 M of $23 M offered
Smallest investment taken
no minimum stated
What was sold
equity, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Lorraine G. LoPresti · Executive Officer
  • Robert Erik Holmlin · Executive Officer, Director
  • Brian L. Halak · Director
  • David L. Barker · Director
  • Tracy Erik Warren · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Lorraine G. LoPresti, Cfo. Source: SEC Form D, newest notice filed Mar 24, 2011. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Bionano Genomics, Inc., its revenue in fiscal 2025 came from these product and service lines: Consumables $13.97 million (49%), Software $6.41 million (22%), Instruments $6.36 million (22%), Service and other revenue $1.76 million (6%).

    Annual report (SEC XBRL) · Dec 2025

  • BioNanomatrix Inc chose not to state its revenue in its newest notice of a funding round (Jul 2024).

    SEC Form D · Jul 2024

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jul 2024

Products and services#

No products or services of BioNanomatrix Inc are on record.

Investors#

6 named in official filings. Open an investor to see everything it has backed.

Investors in BioNanomatrix Inc
InvestorKindAmountRoundRoleSource
Domain Partners VIII, L.P.Fund or asset managernot statednot statedHeld Series B, B-1, C, D and D-1 preferred stock, 10% owner (Form 3, 2018)SEC Form 3
DP VIII Associates, L.P.Fund or asset managernot statednot statedHeld Series B, B-1, C, D and D-1 preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Han CaoPersonnot statednot statedHeld Series B, C, D and D-1 preferred stock (Form 3, 2018)SEC Form 3
LC Fund VI, L.P.Fund or asset managernot statednot statedHeld Series C, D and D-1 preferred stock, 10% owner (Form 3, 2018)SEC Form 3
LC Healthcare Fund I, L.P.Fund or asset managernot statednot statedHeld Series C, D and D-1 preferred stock, 10% owner (Form 3, 2018)SEC Form 3
LC Parallel Fund VI, L.P.Fund or asset managernot statednot statedHeld Series C, D and D-1 preferred stock, 10% owner (Form 3, 2018)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 17 investors.

Largest shareholders today

Institutions holding Bionano Genomics, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by BioNanomatrix Inc
NameRoleNamed in
Alka A. ChaubeyExecutive officerJul 2024
Gulsen Erik KamaExecutive officerJul 2024
Jonathan A. DixonExecutive officerJul 2024
Mark A. OldakowskiExecutive officerJul 2024
R. Erik HolmlinExecutive officerJul 2024
Alka Chaubey, Ph.D., FACMGExecutive officerOct 2023
Gulsen KamaExecutive officerOct 2023
Mark OldakowskiExecutive officerOct 2023
R. Erik Holmlin, Ph.D.Executive officerOct 2023
Christopher StewartExecutive officerOct 2021
Jason A. PriarExecutive officerOct 2021
Richard A. ShippyExecutive officerOct 2021
Soheil A. ShamsExecutive officerOct 2021
Mark BorodkinExecutive officerMar 2019
Mike WardExecutive officerMar 2019
Warren RobinsonExecutive officerMar 2019
Erik R. HolmlinExecutive officerJan 2015
Han R. CaoExecutive officerJan 2015
Joel R. JungExecutive officerJan 2015
Han A. CaoExecutive officerJun 2014
Garth A. MonroeExecutive officerJul 2012
Lorraine G. LoPrestiExecutive officerMar 2011
Robert Erik HolmlinExecutive officerMar 2011
Albert A. LudererDirectorJul 2024
Aleksandar A. RajkovicDirectorJul 2024
Christopher A. TwomeyDirectorJul 2024
David L. BarkerDirectorJul 2024
Hannah A. MamuszkaDirectorJul 2024
Kristiina A. VuoriDirectorJul 2024
R. Erik HolmlinDirectorJul 2024
Vincent A. WongDirectorJul 2024
Yvonne L. LinneyDirectorJul 2024
Albert A. Luderer, Ph.D.DirectorOct 2023
Aleksandar A. Rajkovic, M.D., Ph.D.DirectorOct 2023
David L. Barker, Ph.D.DirectorOct 2023
Kristiina A. Vuori, M.D., Ph.D.DirectorOct 2023
R. Erik Holmlin, Ph.D.DirectorOct 2023
Vincent A. Wong, J.D., M.B.A.DirectorOct 2023
Yvonne A. Linney, Ph.D.DirectorOct 2023
Albert L. Luderer, Ph.D.DirectorMar 2019

Went public since 2018. Its SEC number is that of a company listed on a stock exchange.